Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio sobre la Diabetes Tipo 2 Intratable (CAPTAIN-T2D) (CAPTAIN-T2D)

5 de octubre de 2026 actualizado por: Sparrow Pharmaceuticals

Ensayo de Fase 2 de Clofutriben y Placebo contra la Diabetes Tipo 2 Intratable (CAPTAIN-T2D)

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.

The trial consists of two parts.

Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.

During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

1500

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Arizona
      • Chandler, Arizona, Estados Unidos, 85225
        • Reclutamiento
        • Arizona Clinical Trials - Pecos
        • Contacto:
      • Tucson, Arizona, Estados Unidos, 85711
        • Reclutamiento
        • Arizona Clinical Trials - Broadway
        • Contacto:
    • California
      • Fountain Valley, California, Estados Unidos, 92708
        • Reclutamiento
        • Ark Clinical Research - Fountain Valley
        • Contacto:
      • Huntington Park, California, Estados Unidos, 90255
        • Reclutamiento
        • Velocity Clinical Research, Huntington Park
        • Contacto:
      • La Mesa, California, Estados Unidos, 91942
        • Reclutamiento
        • Velocity Clinical Research - Gardena
        • Contacto:
      • Long Beach, California, Estados Unidos, 90815
        • Reclutamiento
        • Ark Clinical Research - Long Beach
        • Contacto:
      • Los Angeles, California, Estados Unidos, 90057
        • Reclutamiento
        • Velocity Clinical Research, Los Angeles
        • Contacto:
      • Los Angeles, California, Estados Unidos, 90015
        • Reclutamiento
        • Los Angeles Institute for Metabolic Research
        • Contacto:
      • Northridge, California, Estados Unidos, 98433
        • Reclutamiento
        • Amicis Research Center- Nordhoff
        • Contacto:
      • San Diego, California, Estados Unidos, 92120
    • Florida
      • Edgewater, Florida, Estados Unidos, 32132
        • Reclutamiento
        • Velocity Clinical Research, New Smyrna Beach
        • Contacto:
      • Fort Lauderdale, Florida, Estados Unidos, 33312
        • Reclutamiento
        • The Center for Diabetes and Endocrine Care
        • Contacto:
      • Miami, Florida, Estados Unidos, 33173
        • Reclutamiento
        • Admed Research LLC
        • Contacto:
      • New Port Richey, Florida, Estados Unidos, 34652
      • Port Charlotte, Florida, Estados Unidos, 33952
        • Reclutamiento
        • Innovative Research Institute
        • Contacto:
          • Lauren Manager
          • Número de teléfono: (+1) 2832276233
          • Correo electrónico: l.ellis@medpace.com
      • Port Orange, Florida, Estados Unidos, 32127
        • Reclutamiento
        • Progressive Medical Research
        • Contacto:
      • Winter Park, Florida, Estados Unidos, 32789
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30303
        • Reclutamiento
        • Emory University School of Medicine
        • Contacto:
      • Columbus, Georgia, Estados Unidos, 31904
    • Idaho
      • Boise, Idaho, Estados Unidos, 83709
        • Reclutamiento
        • Paradigm Clinical Research - Boise, ID
        • Contacto:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60607
        • Reclutamiento
        • Chicago Clinical Research Institute
        • Contacto:
          • Manognya Clinical Research Manager
          • Número de teléfono: 303 3127913241
          • Correo electrónico: manognya@ccrii.us
    • Iowa
      • West Des Moines, Iowa, Estados Unidos, 50226
        • Reclutamiento
        • Iowa Diabetes and Endocrinology Research Center
        • Contacto:
          • Crystal Manager
          • Número de teléfono: 515-207-7486
          • Correo electrónico: choffman@iderc.com
    • Kansas
      • Wichita, Kansas, Estados Unidos, 67226
        • Reclutamiento
        • Alliance for Multispecialty Research - Wichita East
        • Contacto:
    • Kentucky
      • Edgewood, Kentucky, Estados Unidos, 41017
        • Reclutamiento
        • St. Elizabeth Healthcare
        • Contacto:
    • Louisiana
      • Lafayette, Louisiana, Estados Unidos, 70508
        • Reclutamiento
        • Velocity Clinical Research, Lafayette
        • Contacto:
      • Metairie, Louisiana, Estados Unidos, 70006
        • Reclutamiento
        • NOLA Care Clinical Research
        • Contacto:
      • New Orleans, Louisiana, Estados Unidos, 70112
        • Reclutamiento
        • Tulane University School of Medicine
        • Contacto:
    • Maryland
      • Rockville, Maryland, Estados Unidos, 20854
        • Reclutamiento
        • Velocity Clinical Research, Rockville
        • Contacto:
    • Massachusetts
      • Springfield, Massachusetts, Estados Unidos, 011030
    • Michigan
      • Troy, Michigan, Estados Unidos, 48085
        • Reclutamiento
        • Oakland Medical Research Center
        • Contacto:
          • Juliejo (Julie) Clinical Research Manager
          • Número de teléfono: 248-687-7412
          • Correo electrónico: juliejolafave@msn.com
    • Nebraska
      • Lincoln, Nebraska, Estados Unidos, 68510
        • Reclutamiento
        • Velocity Clinical Research, Lincoln
        • Contacto:
      • Omaha, Nebraska, Estados Unidos, 68134
        • Reclutamiento
        • Velocity Clinical Research, Omaha
        • Contacto:
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89148
        • Reclutamiento
        • Palm Research Center, Inc.
        • Contacto:
      • Las Vegas, Nevada, Estados Unidos, 89108
    • New York
      • Albany, New York, Estados Unidos, 12203
        • Reclutamiento
        • Albany Medical College
        • Contacto:
          • Mohammed Manager
          • Número de teléfono: 518-264-4462
          • Correo electrónico: ismailmoh@amc.edu
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27514
        • Reclutamiento
        • University of North Carolina at Chapel Hill
        • Contacto:
      • Greenville, North Carolina, Estados Unidos, 27834
        • Reclutamiento
        • Physicians East
        • Contacto:
      • Morehead City, North Carolina, Estados Unidos, 28557
      • Wilmington, North Carolina, Estados Unidos, 28401
        • Reclutamiento
        • PMG Research of Wilmington, LLC
        • Contacto:
          • Kevin Manager
          • Número de teléfono: 910.815.6108
          • Correo electrónico: cannon1099@me.com
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • Reclutamiento
        • Velocity Clinical Research, Cincinnati, Mt. Auburn
        • Contacto:
      • Cincinnati, Ohio, Estados Unidos, 45242
        • Reclutamiento
        • Velocity Clinical Research - Cincinnati, Blue Ash
        • Contacto:
      • Columbus, Ohio, Estados Unidos, 43201
        • Reclutamiento
        • Endocrinology Associates, Inc
        • Contacto:
      • Columbus, Ohio, Estados Unidos, 43215
        • Reclutamiento
        • Remington Davis, Inc
        • Contacto:
          • Tsunami Clinical Research Manager
          • Número de teléfono: 614-487-2560
          • Correo electrónico: Tbrisco@remdavis.com
    • Oregon
      • Eugene, Oregon, Estados Unidos, 97404
        • Reclutamiento
        • Willamette Valley Clinical Studies
        • Contacto:
          • Patricia Manager
          • Número de teléfono: 541-461-0132
          • Correo electrónico: drpatb@aol.com
    • Pennsylvania
      • West Chester, Pennsylvania, Estados Unidos, 19380
        • Reclutamiento
        • Suburban Research Associates
        • Contacto:
    • South Carolina
      • Anderson, South Carolina, Estados Unidos, 29621
        • Reclutamiento
        • Velocity Clinical Research, Anderson
        • Contacto:
      • Mt. Pleasant, South Carolina, Estados Unidos, 29464
        • Reclutamiento
        • Accellacare Charleston
        • Contacto:
    • Texas
      • Austin, Texas, Estados Unidos, 78759
        • Reclutamiento
        • Velocity Clinical Research, Austin
        • Contacto:
      • Dallas, Texas, Estados Unidos, 75230
        • Reclutamiento
        • Velocity Clinical Research - Dallas
        • Contacto:
      • Houston, Texas, Estados Unidos, 77040
        • Reclutamiento
        • Juno Research, LLC
        • Contacto:
      • Lampasas, Texas, Estados Unidos, 76550
        • Reclutamiento
        • Radiance Clinical Research
        • Contacto:
      • Lewisville, Texas, Estados Unidos, 75057
        • Reclutamiento
        • Alliance Clinical - Lewisville (Epic Clinical Research)
        • Contacto:
      • Mission, Texas, Estados Unidos, 78572
        • Reclutamiento
        • Texas Valley Clinical Research - Mission, TX
        • Contacto:
      • Round Rock, Texas, Estados Unidos, 78681
        • Reclutamiento
        • Texas Diabetes & Endocrinology, P.A. - Round Rock
        • Contacto:
          • Olivia Clinical Research Manager
          • Número de teléfono: 512-334-3505
          • Correo electrónico: knutty@tderesearch.com
      • San Antonio, Texas, Estados Unidos, 78229
        • Reclutamiento
        • Diabetes & Glandular Disease Clinic, P.A.
        • Contacto:
      • San Antonio, Texas, Estados Unidos, 78251
        • Reclutamiento
        • Texas Valley Clinical Research - San Antonio TX
        • Contacto:
      • Seabrook, Texas, Estados Unidos, 77586
        • Reclutamiento
        • Elevate Clinical Research
        • Contacto:
      • Weslaco, Texas, Estados Unidos, 78596
        • Reclutamiento
        • Texas Valley Clinical Research, LLC
        • Contacto:
    • Utah
      • West Jordan, Utah, Estados Unidos, 84088
        • Reclutamiento
        • Velocity Clinical Research, Salt Lake City
        • Contacto:
    • Virginia
      • Suffolk, Virginia, Estados Unidos, 23435
        • Reclutamiento
        • Velocity Clinical Research, Suffolk
        • Contacto:
      • Vienna, Virginia, Estados Unidos, 22182

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • From Screening 1

    • Age at least 18 years.

    • HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).

    • Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).

    • Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.

    • Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.

    • At least one of the following

      • ≥3 stable and adequate ADMs;
      • diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
      • hypertension requiring ≥2 adequately dosed AHMs;
      • adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
      • adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
      • evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
      • or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.

At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.

At Screening 2

  • HbA1c ≥7.5% at Screening 2. At Day 1
  • No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.

Exclusion Criteria:

  • New-onset diabetes (onset <1 year in the past).

  • Unwillingness to maintain with current glucose-lowering regimen during the trial.

  • Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.

  • Unwillingness to comply with CGM or other trial procedures.

  • Investigator considers the patient will otherwise be unwilling or unable to complete the trial.

  • Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.

  • Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).

  • Any of the following in medical history:

    • Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
    • A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
    • Hypersensitivity or severe reaction to dexamethasone;
    • Pheochromocytoma, or suspicion thereof;
    • Anorexia, or other eating disorder;
    • Glucocorticoid resistance;
    • Multiple sclerosis;
    • Significant hepatic impairment (e.g., Child-Pugh Class B or C);
    • Idiopathic thrombocytopenic purpura;
    • Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
    • Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
    • Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
    • Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
    • Any of the following in medication history:
    • Any of the excluded medications listed in Section 6.9;
    • Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
    • Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
    • Pregnancy (including a positive urine test) or current breast feeding.

From Screening 2

• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:

  • wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
  • a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
  • supraclavicular/dorsocervical fat accumulation;
  • irounding of the face (especially compared with prior photos);
  • skin changes (violaceous striae, skin thinning, or excessive bruising);
  • proximal muscle weakness on exam; or
  • history of deep vein thrombosis/pulmonary embolism.
  • Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
  • Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
  • Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
  • Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
  • Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
  • Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
  • Known hypersensitivity to clofutriben or to any of the product

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Dose 1

clofutriben .2 mg oral tablet daily

HSD-1 inhibitor

Otros nombres:
  • SPI-62
  • ASP3662
Experimental: Dose 2

clofutriben 2mg oral tablet daily

HSD-1 inhibitor

Otros nombres:
  • SPI-62
  • ASP3662
Experimental: Dose 3

clofutriben 6mg oral tablet daily

HSD-1 inhibitor

Otros nombres:
  • SPI-62
  • ASP3662
Experimental: Dose 4

clofutriben 12 mg oral tablet daily

HSD-1 inhibitor

Otros nombres:
  • SPI-62
  • ASP3662
Comparador de placebos: placebo

placebo control oral tablet daily

Placebo

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Periodo de tiempo: 8-10 hours after the dexamethasone 1 mg dose.

To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose.

8-10 hours after the dexamethasone 1 mg dose.
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Periodo de tiempo: 24 weeks.

To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Periodo de tiempo: 24 weeks

To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
To evaluate the safety of clofutriben in participants with T2D and EC.
Periodo de tiempo: From enrollment until end of trial 9 month

Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose

From enrollment until end of trial 9 month

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de noviembre de 2025

Finalización primaria (Estimado)

31 de diciembre de 2027

Finalización del estudio (Estimado)

30 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

30 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

18 de diciembre de 2025

Publicado por primera vez (Actual)

22 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir